ResMed (RMD) 10-Q 31 Oct 14 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Sep. 30, 2014	Oct. 21, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2015	'
Document Fiscal Period Focus	'Q1	'
Entity Registrant Name	'RESMED INC	'
Entity Central Index Key	'0000943819	'
Current Fiscal Year End Date	'--06-30	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	139,444,592

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$881,694	$905,730
Accounts receivable, net of allowance for doubtful accounts of $10,848 and $10,971 at September 30, 2014 and June 30, 2014, respectively	328,591	359,593
Inventories (note 3)	197,226	165,418
Deferred income taxes	36,270	31,908
Income taxes receivable	2,577	14,853
Prepaid expenses and other current assets	88,392	78,707
Total current assets	1,534,750	1,556,209
Non-current assets:	'	'
Property, plant and equipment, net (note 4)	419,786	434,277
Goodwill and other intangible assets, net (note 6)	323,746	334,510
Deferred income taxes	13,538	18,755
Other assets	17,633	17,211
Total non-current assets	774,703	804,753
Total assets	2,309,453	2,360,962
Current liabilities:	'	'
Accounts payable	76,248	85,405
Accrued expenses	124,235	130,656
Deferred revenue	39,543	42,370
Income taxes payable	13,619	10,392
Deferred income taxes	651	717
Current portion of long-term debt (note 7)	'	18
Total current liabilities	254,296	269,558
Non-current liabilities:	'	'
Deferred income taxes	10,002	10,716
Deferred revenue	14,489	16,352
Long-term debt (note 7)	375,701	300,770
Income taxes payable	1,754	5,318
Total non-current liabilities	401,946	333,156
Total liabilities	656,242	602,714
Commitments and contingencies (note 12)	'	'
Stockholders' equity: (note 10)	'	'
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued	'	'
Common stock, $0.004 par value, 350,000,000 shares authorized; 177,030,185 issued and 139,752,203 outstanding at September 30, 2014 and 176,747,039 issued and 140,304,544 outstanding at June 30, 2014	559	561
Additional paid-in capital	1,136,528	1,117,644
Retained earnings	1,824,457	1,780,396
Treasury stock, at cost, 37,277,982 shares at September 30, 2014, and 36,442,495 shares at June 30, 2014	-1,334,782	-1,291,910
Accumulated other comprehensive income	26,449	151,557
Total stockholders' equity	1,653,211	1,758,248
Total liabilities and stockholders' equity	$2,309,453	$2,360,962

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, except Share data, unless otherwise specified
Condensed Consolidated Balance Sheets [Abstract]	'	'
Accounts receivable, allowance for doubtful accounts	$10,848	$10,971
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	177,030,185	176,747,039
Common stock, shares outstanding	139,752,203	140,304,544
Treasury stock, shares held	37,277,982	36,442,495

Condensed_Consolidated_Stateme

Condensed Consolidated Statements Of Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidated Statements Of Income [Abstract]	'	'
Net revenue	$380,399	$357,662
Cost of sales	143,086	129,680
Gross profit	237,313	227,982
Operating expenses:	'	'
Selling, general and administrative	110,520	101,323
Research and development	30,024	27,363
Amortization of acquired intangible assets	2,094	2,412
Total operating expenses	142,638	131,098
Income from operations	94,675	96,884
Other income, net:	'	'
Interest income, net	5,584	6,414
Other, net	1,671	-1,228
Total other income, net	7,255	5,186
Income before income taxes	101,930	102,070
Income taxes	18,670	21,140
Net income	$83,260	$80,930
Basic earnings per share	$0.59	$0.57
Diluted earnings per share (note 2)	$0.58	$0.56
Dividend declared per share	$0.28	$0.25
Basic shares outstanding	140,127	142,005
Diluted shares outstanding	142,683	145,456

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements Of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Condensed Consolidated Statements Of Comprehensive Income [Abstract]	'	'
Net income	$83,260	$80,930
Other comprehensive income:	'	'
Foreign currency translation gain (loss) adjustments	-125,108	38,203
Comprehensive income	($41,848)	$119,133

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income	$83,260	$80,930
Adjustment to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	18,582	17,870
Gain on divestment of business	-709	'
Stock-based compensation costs	11,367	10,816
Foreign currency revaluation	451	-1,653
Excess tax benefit from stock-based compensation arrangements	-2,575	-2,241
Changes in operating assets and liabilities, net of effect of acquisitions:	'	'
Accounts receivable, net	20,804	40,268
Inventories, net	-37,897	-26,847
Prepaid expenses, net deferred income taxes and other current assets	-15,168	-4,451
Accounts payable, accrued expenses and other liabilities	8,421	-24,267
Net cash provided by operating activities	86,536	90,425
Cash flows from investing activities:	'	'
Purchases of property, plant and equipment	-20,681	-16,752
Patent registration costs	-2,366	-1,679
Business acquisitions, net of cash acquired	-7,318	'
Investments in cost-method investments	-500	-675
Proceeds from divestiture of business	468	'
Payments on maturity of foreign currency contracts	-11,206	-2,486
Net cash used in investing activities	-41,603	-21,592
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock, net	4,930	6,470
Excess tax benefit from stock-based compensation arrangements	2,575	2,241
Purchases of treasury stock	-46,803	-22,822
Payment of business combination contingent consideration	-458	-442
Proceeds from borrowings, net of borrowing costs	75,000	60,000
Repayment of borrowings	-10	-9
Dividend paid	-39,199	-35,478
Net cash used in financing activities	-3,965	9,960
Effect of exchange rate changes on cash	-65,004	21,733
Net increase in cash and cash equivalents	-24,036	100,526
Cash and cash equivalents at beginning of period	905,730	876,048
Cash and cash equivalents at end of period	881,694	976,574
Supplemental disclosure of cash flow information:	'	'
Income taxes paid, net of refunds	14,373	39,612
Interest paid	1,233	1,599
Fair value of assets acquired, excluding cash	7,342	'
Liabilities assumed	-3,168	'
Goodwill on acquisition	6,454	'
Deferred payments	-2,405	'
Fair value of contingent consideration	-905	'
Total purchase price, excluding contingent consideration	$7,318	'

Summary_Of_Significant_Account

Summary Of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Summary Of Significant Accounting Policies	'
	(1)       Summary of Significant Accounting Policies
	Organization and Basis of Presentation
	ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group.  Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.  Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States.  Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods.  The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2015.
	The condensed consolidated financial statements for the three months ended September 30, 2014 and 2013 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2014.
	New Accounting Pronouncements
	In May, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company beginning in the first quarter of fiscal year 2018. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

Earnings_Per_Share

Earnings Per Share	3 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	(2)        Earnings Per Share
	Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.
	The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 154,551 and 209,856 for the three months ended September 30, 2014 and 2013, respectively, as the effect of exercising these options would have been anti-dilutive.
	Basic and diluted earnings per share for the three months ended September 30, 2014 and 2013 are calculated as follows (in thousands except per share data):
			Three Months Ended September 30,
			2014		2013
		Numerator:
		Net Income, used in calculating diluted earnings per share	$	83,260	$	80,930
		Denominator:
		Basic weighted-average common shares outstanding		140,127		142,005
		Effect of dilutive securities:
		Stock options and restricted stock units		2,556		3,451
		Diluted weighted average shares		142,683		145,456
		Basic earnings per share	$	0.59	$	0.57
		Diluted earnings per share	$	0.58	$	0.56

Inventories

Inventories	3 Months Ended
	Sep. 30, 2014
Inventories [Abstract]	'
Inventories	'
	(3)        Inventories
	Inventories were comprised of the following at September 30, 2014 and June 30, 2014 (in thousands):
			30-Sep-14		30-Jun-14
		Raw materials	$	58,024	$	53,680
		Work in progress		3,761		3,358
		Finished goods		135,441		108,380
		Total inventories	$	197,226	$	165,418

Property_Plant_And_Equipment

Property, Plant And Equipment	3 Months Ended
	Sep. 30, 2014
Property, Plant And Equipment [Abstract]	'
Property, Plant And Equipment	'
	(4)        Property, Plant and Equipment
	Property, plant and equipment were comprised of the following as of September 30, 2014 and June 30, 2014 (in thousands):
			30-Sep-14		30-Jun-14
		Machinery and equipment	$	196,401	$	200,929
		Computer equipment		135,868		133,157
		Furniture and fixtures		41,168		42,631
		Vehicles		3,583		4,757
		Clinical, demonstration and rental equipment		93,503		101,453
		Leasehold improvements		29,032		30,361
		Land		59,494		62,468
		Buildings		254,511		266,771
				813,560		842,527
		Accumulated depreciation and amortization		-393,774		-408,250
		Property, plant and equipment, net	$	419,786	$	434,277

CostMethod_Investments

Cost-Method Investments	3 Months Ended
	Sep. 30, 2014
Cost-Method Investments [Abstract]	'
Cost-Method Investments	'
	(5)        Cost-Method Investments
	The aggregate carrying amount of our cost-method investments at September 30, 2014 and June 30, 2014, was $15.4 million and $14.9 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.
	We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered.  We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows.  During the three months ended September 30, 2014 and 2013, we recognized $Nil and $Nil, respectively, of impairment losses related to our cost-method investments.  We have determined that the fair value of our investments exceed their carrying values.
	The following table shows a reconciliation of the changes in our cost-method investments during the three months ended September 30, 2014 and 2013 (in thousands):
			Three Months Ended September 30,
			2014		2013
		Balance at the beginning of the period	$	14,850	$	4,000
		Investments		500		675
		Balance at the end of the period	$	15,350	$	4,675

Goodwill_And_Other_Intangible_

Goodwill And Other Intangible Assets, Net	3 Months Ended
	Sep. 30, 2014
Goodwill And Other Intangible Assets, Net [Abstract]	'
Goodwill And Other Intangible Assets, Net	'
	(6)      Goodwill and Other Intangible Assets, net
	Goodwill
	Changes in the carrying amount of goodwill for the three months ended September 30, 2014, and 2013 were as follows (in thousands):
			Three Months Ended September 30,
			2014		2013
		Balance at the beginning of the period	$	289,312	$	274,829
		Business acquisition		6,454		-
		Foreign currency translation adjustments		-18,502		8,616
		Balance at the end of the period	$	277,264	$	283,445
	Other Intangible Assets
	Other intangible assets are comprised of the following as of September 30, 2014, and June 30, 2014 (in thousands):
			30-Sep-14		June 30, 2014
		Developed/core product technology	$	70,677	$	76,015
		Accumulated amortization		-51,642		-54,073
		Developed/core product technology, net		19,035		21,942
		Trade names		2,803		2,784
		Accumulated amortization		-2,508		-2,697
		Trade names, net		295		87
		Non-compete agreements		1,982		2,135
		Accumulated amortization		-1,715		-1,768
		Non compete agreements, net		267		367
		Customer relationships		28,368		24,593
		Accumulated amortization		-19,834		-20,877
		Customer relationships, net		8,534		3,716
		Patents		67,872		70,734
		Accumulated amortization		-49,521		-51,648
		Patents, net		18,351		19,086
		Total other intangibles, net	$	46,482	$	45,198
	Intangible assets consist of patents, customer relationships, trade names, non-compete agreements and developed/core product technology.  We amortize intangible assets over the estimated useful life of the assets, generally between two and nine years. There are no expected residual values related to these intangible assets.

LongTerm_Debt

Long-Term Debt	3 Months Ended
	Sep. 30, 2014
Long-Term Debt [Abstract]	'
Long-Term Debt	'
	(7)        Long-Term Debt
	Long-term debt at September 30, 2014 and June 30, 2014 consists of the following (in thousands):
			30-Sep-14		June 30, 2014
		Current long-term debt	$	-	$	18
		Non-current long-term debt		375,701		300,770
		Total long-term debt	$	375,701	$	300,788
	Credit Facility
	On October 31, 2013, we entered into a credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger. Our obligations under the credit agreement are guaranteed by ResMed Corp. and ResMed Motor Technologies Inc., two of our U.S. subsidiaries.
	The credit agreement provides a $700 million senior unsecured five-year revolving credit facility, with an uncommitted option to increase the credit facility by an additional $300 million. The credit facility also includes a $25 million sublimit for letters of credit. The credit facility terminates on October 31, 2018, when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At September 30, 2014, the interest rate that was being charged on the outstanding principal amount was  1.2%.  An applicable commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility.
	When we entered into the credit agreement, we used a portion of the proceeds from the initial funding of the credit facility to repay the outstanding balance under our previous revolving credit facility with Union Bank, N.A and other lenders. On that repayment, the previous credit agreement, dated as of February 10, 2011, between us and lenders (including Union Bank, N.A., as administrative agent, swing line lender and L/C Issuer, HSBC Bank USA, National Association, as syndication agent and Union Bank, N.A., HSBC Bank USA, National Association, Commonwealth Bank of Australia and Wells Fargo Bank), was terminated and the commitments under the previous credit agreement were also terminated.
	Our obligations under the current credit agreement are unsecured but are guaranteed by two of our U.S. subsidiaries. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the credit agreement. Events of default under the credit agreement include failure to make payments when due, the occurrence of a default in the performance of any covenants in the credit agreement or related documents, or certain changes of control of ResMed Inc., ResMed Corp., ResMed Motor Technologies Inc., ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP Holdings LLC.
	At September 30, 2014, there was $375.0 million outstanding under the credit agreement.

Product_Warranties

Product Warranties	3 Months Ended
	Sep. 30, 2014
Product Warranties [Abstract]	'
Product Warranties	'
	(8)        Product Warranties
	Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the three months ended September 30, 2014 and 2013 are as follows (in thousands):
			Three Months Ended September 30,
			2014		2013
		Balance at the beginning of the period	$	11,798	$	16,011
		Warranty accruals for the period		3,376		2,796
		Warranty costs incurred for the period		-1,567		-2,270
		Foreign currency translation adjustments		-714		368
		Balance at the end of the period	$	12,893	$	16,905

StockBased_Employee_Compensati

Stock-Based Employee Compensation	3 Months Ended
	Sep. 30, 2014
Stock-Based Employee Compensation [Abstract]	'
Stock-Based Employee Compensation	'
	(9)        Stock-Based Employee Compensation
	We measure the compensation expense of all stock-based awards at fair value on the grant date.  We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the “ESPP”) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period.  The fair value of performance restricted stock units which contain a market condition, are estimated using a Monte-Carlo simulation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.
	We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions:
			Three Months Ended September 30,
			2014		2013
		Stock options:
		Weighted average grant date fair value	$	-	$	-
		Weighted average risk-free interest rate		-		-
		Expected option life in years		-		-
		Dividend yield		-		-
		Expected volatility		-		-
		ESPP purchase rights:
		Weighted average risk-free interest rate		0.10%		0.10%
		Expected option life in years		6 months		6 months
		Dividend yield		2.00%		1.44%
		Expected volatility		24%		24%

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	(10)      Stockholders’ Equity
	Common Stock.    During the three months ended September 30, 2014 and 2013 we repurchased 0.8 million and 0.4 million shares at a cost of  $42.9 million and $21.1 million, respectively. Since the inception of our share repurchase programs and through September 30, 2014, we have repurchased a total of 37.3 million shares at a cost of $1.3 billion.  Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share.  At September 30, 2014, 17.4 million additional shares can be repurchased under the approved share repurchase program.
	Preferred Stock.    In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at September 30, 2014 and June 30, 2014.
	Stock Options and Restricted Stock Units.    We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”).  These options and restricted stock units have expiration dates of seven years from the date of grant and vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.
	The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 43.7 million shares. The number of securities remaining available for future issuance under the 2009 Plan at September 30, 2014 is 16.2 million.  The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any “full-value award,” which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards.  The maximum number of shares, that may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant’s initial year of hiring, when up to 4.5 million shares of our common stock may be granted).
	At September 30, 2014, there were $62.1 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.1 years.  The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at September 30, 2014 was $225.0 million and $93.9 million, respectively.  The aggregate intrinsic value of the options exercised during the three months ended September 30, 2014 and 2013, was $9.7 million and $11.5 million, respectively.
	The following table summarizes option activity during the three months ended September 30, 2014:
				Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
		Outstanding at beginning of period	4,687,220	$	24.45	2.6
		Granted	-		-
		Exercised	-297,969		18.56
		Forfeited	-13,823		34.00
		Outstanding at end of period	4,375,428	$	24.82	2.4
		Exercise price range of granted options	-
		Options exercisable at end of period	3,399,349	$	21.66
	The following table summarizes the activity of restricted stock units during the three months ended September 30, 2014:
				Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
		Outstanding at beginning of period	2,448,331	$	38.58	1.3
		Granted	1,500		47.08
		Vested	-33,149		30.95
		Forfeited	-24,189		36.86
		Outstanding at end of period	2,392,493	$	38.70	1.1
	Employee Stock Purchase Plan (the “ESPP”).  Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year.  At September 30, 2014, the number of shares remaining available for future issuance under the ESPP is  1.8 million shares.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2014
Fair Value Measurements [Abstract]	'
Fair Value Measurements	'
	(11)       Fair Value Measurements
	In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The hierarchies of inputs are as follows:
		·		Level 1:Input prices quoted in an active market for identical financial assets or liabilities;
		·		Level 2:Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and
		·		Level 3:Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.
	The following table summarizes our financial assets and liabilities, as at September 30, 2014 and June 30, 2014, using the valuation input hierarchy (in thousands):
				Level 1		Level 2		Level 3		Total
		Balances at September 30, 2014
		Foreign currency hedging instruments, net	$	-	$	-2,048	$	-	$	-2,048
		Business acquisition contingent consideration	$	-	$	-	$	-875	$	-875
		Balances at June 30, 2014
		Foreign currency hedging instruments, net	$	-	$	-2,270	$	-	$	-2,270
		Business acquisition contingent consideration	$	-	$	-	$	-480	$	-480
	We determine the fair value of our financial assets and liabilities as follows:
	Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.
	Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones.  Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.
	The following is a reconciliation of changes in the fair value of contingent consideration for the three months ended September 30, 2014 (in thousands):
			Three Months Ended September 30, 2014
		Balance at the beginning of the period	$	-480
		Acquisition date fair value of contingent consideration		-905
		Changes in fair value included in operating income		132
		Payments		458
		Foreign currency translation adjustments		-80
		Balance at the end of the period	$	-875
	We did not have any significant non-financial assets or liabilities measured at fair value on September 30, 2014 or June 30, 2014.

Legal_Actions_And_Contingencie

Legal Actions And Contingencies	3 Months Ended
	Sep. 30, 2014
Legal Actions And Contingencies [Abstract]	'
Legal Actions And Contingencies	'
	(12)      Legal Actions and Contingencies
	Litigation
	In the normal course of business, we are subject to routine litigation incidental to our business.  While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.
	Contingent Obligations Under Recourse Provisions
	We use independent leasing companies to provide financing to certain customers for the purchase of our products.  In some cases, we are contingently liable in the event of a customer default, to the leasing companies, within certain limits, for unpaid installment receivables transferred to the leasing companies.  The gross amount of receivables sold with recourse during the three months ended September 30, 2014 and 2013, amounted to $2.0 million and $0.8 million, respectively.  The maximum potential amount of contingent liability under these arrangements at September 30, 2014 and June 30, 2014 were $5.2 million, and $4.9 million, respectively.  The recourse liability recognized by us at September 30, 2014 and June 30, 2014, in relation to these arrangements was $0.5 million and $0.5 million, respectively.

Derivative_Instruments_And_Hed

Derivative Instruments And Hedging Activities	3 Months Ended
	Sep. 30, 2014
Derivative Instruments And Hedging Activities [Abstract]	'
Derivative Instruments And Hedging Activities	'
	(13)      Derivative Instruments and Hedging Activities
	We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations.  We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows.  The terms of such foreign currency hedging contracts generally do not exceed three years.  The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars.  Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments.
	We do not designate these foreign currency contracts as hedges.  We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income.  We do not enter into financial instruments for trading or speculative purposes.
	We held foreign currency instruments with notional amounts totaling $405.8 million and $473.7 million at September 30, 2014 and June 30, 2014, respectively, to hedge foreign currency fluctuations.  These contracts mature at various dates prior to September 30, 2017.
	The following table summarizes the amount and location of our derivative financial instruments as of September 30, 2014 and June 30, 2014 (in thousands):
			30-Sep-14		30-Jun-14		Balance Sheet Caption
		Foreign currency hedging instruments	$	557	$	456		Other assets - current
		Foreign currency hedging instruments		518		489		Other assets - non current
		Foreign currency hedging instruments		-3,123		-3,215		Accrued expenses
			$	-2,048	$	-2,270
	The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the three months ended September 30, 2014 and September 30, 2013, respectively (in thousands):
			Gain /(Loss) Recognized				Income Statement Caption
			Three Months Ended September 30,
			2014		2013
		Foreign currency hedging instruments	$	-11,054	$	-3,156		Other, net
		Other foreign-currency-denominated transactions		12,148		1,741		Other, net
			$	1,094	$	-1,415
	We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments.  We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.

Business_Combinations

Business Combinations	3 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Combinations	'
	(14)       Business Combinations
	During the three months ended September 30, 2014 we acquired two, Australian-based distributors of equipment and services for the treatment of sleep-disordered breathing and respiratory disorders.  These acquisitions have been accounted for as business combinations using purchase accounting and are included in our consolidated financial statements from their respective acquisition dates.  The acquisitions are not considered a material business combination and accordingly pro forma information is not provided.  The acquisitions were funded through cash on-hand and we have not incurred any material acquisition related costs.
	We have completed the preliminary purchase price allocation for the above acquisitions during the quarter. The cost of the acquisitions has been allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. As part of the preliminary purchase price allocation, we recognized an intangible asset relating to customer relationships of $6.0 million, with an estimated useful life of 5 years, and goodwill of $6.5 million.  The goodwill recognized as part of these acquisitions, which is not deductible for tax purposes, mainly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future.

Summary_Of_Significant_Account1

Summary Of Significant Accounting Policies (Policy)	3 Months Ended
	Sep. 30, 2014
Summary Of Significant Accounting Policies [Abstract]	'
Organization And Basis Of Presentation	'
	Organization and Basis of Presentation
	ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group.  Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea.  Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States.  Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.  In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods.  The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2015.
	The condensed consolidated financial statements for the three months ended September 30, 2014 and 2013 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2014.
New Accounting Pronouncements	'
	New Accounting Pronouncements
	In May, 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company beginning in the first quarter of fiscal year 2018. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule Of Basic And Diluted Earnings Per Share	'
			Three Months Ended September 30,
			2014		2013
		Numerator:
		Net Income, used in calculating diluted earnings per share	$	83,260	$	80,930
		Denominator:
		Basic weighted-average common shares outstanding		140,127		142,005
		Effect of dilutive securities:
		Stock options and restricted stock units		2,556		3,451
		Diluted weighted average shares		142,683		145,456
		Basic earnings per share	$	0.59	$	0.57
		Diluted earnings per share	$	0.58	$	0.56

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Sep. 30, 2014
Inventories [Abstract]	'
Schedule Of Inventories	'
			30-Sep-14		30-Jun-14
		Raw materials	$	58,024	$	53,680
		Work in progress		3,761		3,358
		Finished goods		135,441		108,380
		Total inventories	$	197,226	$	165,418

Property_Plant_And_Equipment_T

Property, Plant And Equipment (Tables)	3 Months Ended
	Sep. 30, 2014
Property, Plant And Equipment [Abstract]	'
Components Of Property, Plant And Equipment	'
			30-Sep-14		30-Jun-14
		Machinery and equipment	$	196,401	$	200,929
		Computer equipment		135,868		133,157
		Furniture and fixtures		41,168		42,631
		Vehicles		3,583		4,757
		Clinical, demonstration and rental equipment		93,503		101,453
		Leasehold improvements		29,032		30,361
		Land		59,494		62,468
		Buildings		254,511		266,771
				813,560		842,527
		Accumulated depreciation and amortization		-393,774		-408,250
		Property, plant and equipment, net	$	419,786	$	434,277

CostMethod_Investments_Tables

Cost-Method Investments (Tables)	3 Months Ended
	Sep. 30, 2014
Cost-Method Investments [Abstract]	'
Schedule Of Reconciliation Of Changes In Cost-Method Investments	'
			Three Months Ended September 30,
			2014		2013
		Balance at the beginning of the period	$	14,850	$	4,000
		Investments		500		675
		Balance at the end of the period	$	15,350	$	4,675

Goodwill_And_Other_Intangible_1

Goodwill And Other Intangible Assets, Net (Tables)	3 Months Ended
	Sep. 30, 2014
Goodwill And Other Intangible Assets, Net [Abstract]	'
Schedule Of Changes In Carrying Amount Of Goodwill	'
			Three Months Ended September 30,
			2014		2013
		Balance at the beginning of the period	$	289,312	$	274,829
		Business acquisition		6,454		-
		Foreign currency translation adjustments		-18,502		8,616
		Balance at the end of the period	$	277,264	$	283,445
Schedule Of Other Intangible Assets	'
			30-Sep-14		June 30, 2014
		Developed/core product technology	$	70,677	$	76,015
		Accumulated amortization		-51,642		-54,073
		Developed/core product technology, net		19,035		21,942
		Trade names		2,803		2,784
		Accumulated amortization		-2,508		-2,697
		Trade names, net		295		87
		Non-compete agreements		1,982		2,135
		Accumulated amortization		-1,715		-1,768
		Non compete agreements, net		267		367
		Customer relationships		28,368		24,593
		Accumulated amortization		-19,834		-20,877
		Customer relationships, net		8,534		3,716
		Patents		67,872		70,734
		Accumulated amortization		-49,521		-51,648
		Patents, net		18,351		19,086
		Total other intangibles, net	$	46,482	$	45,198

LongTerm_Debt_Tables

Long-Term Debt (Tables)	3 Months Ended
	Sep. 30, 2014
Long-Term Debt [Abstract]	'
Schedule Of Long-Term Debt	'
			30-Sep-14		June 30, 2014
		Current long-term debt	$	-	$	18
		Non-current long-term debt		375,701		300,770
		Total long-term debt	$	375,701	$	300,788

Product_Warranties_Tables

Product Warranties (Tables)	3 Months Ended
	Sep. 30, 2014
Product Warranties [Abstract]	'
Schedule Of Changes In Liability For Warranty Costs	'
			Three Months Ended September 30,
			2014		2013
		Balance at the beginning of the period	$	11,798	$	16,011
		Warranty accruals for the period		3,376		2,796
		Warranty costs incurred for the period		-1,567		-2,270
		Foreign currency translation adjustments		-714		368
		Balance at the end of the period	$	12,893	$	16,905

StockBased_Employee_Compensati1

Stock-Based Employee Compensation (Tables)	3 Months Ended
	Sep. 30, 2014
Stock-Based Employee Compensation [Abstract]	'
Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted	'
			Three Months Ended September 30,
			2014		2013
		Stock options:
		Weighted average grant date fair value	$	-	$	-
		Weighted average risk-free interest rate		-		-
		Expected option life in years		-		-
		Dividend yield		-		-
		Expected volatility		-		-
		ESPP purchase rights:
		Weighted average risk-free interest rate		0.10%		0.10%
		Expected option life in years		6 months		6 months
		Dividend yield		2.00%		1.44%
		Expected volatility		24%		24%

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	3 Months Ended
	Sep. 30, 2014
Stockholders' Equity [Abstract]	'
Schedule Of Option Activity	'
				Weighted Average Exercise Price		Weighted Average Remaining Contractual Term in Years
		Outstanding at beginning of period	4,687,220	$	24.45	2.6
		Granted	-		-
		Exercised	-297,969		18.56
		Forfeited	-13,823		34.00
		Outstanding at end of period	4,375,428	$	24.82	2.4
		Exercise price range of granted options	-
		Options exercisable at end of period	3,399,349	$	21.66
Schedule Of Activity Of Restricted Stock Units	'
				Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Term in Years
		Outstanding at beginning of period	2,448,331	$	38.58	1.3
		Granted	1,500		47.08
		Vested	-33,149		30.95
		Forfeited	-24,189		36.86
		Outstanding at end of period	2,392,493	$	38.70	1.1

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2014
Fair Value Measurements [Abstract]	'
Summary Of Financial Assets And Liabilities	'
				Level 1		Level 2		Level 3		Total
		Balances at September 30, 2014
		Foreign currency hedging instruments, net	$	-	$	-2,048	$	-	$	-2,048
		Business acquisition contingent consideration	$	-	$	-	$	-875	$	-875
		Balances at June 30, 2014
		Foreign currency hedging instruments, net	$	-	$	-2,270	$	-	$	-2,270
		Business acquisition contingent consideration	$	-	$	-	$	-480	$	-480
Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs	'
			Three Months Ended September 30, 2014
		Balance at the beginning of the period	$	-480
		Acquisition date fair value of contingent consideration		-905
		Changes in fair value included in operating income		132
		Payments		458
		Foreign currency translation adjustments		-80
		Balance at the end of the period	$	-875

Derivative_Instruments_And_Hed1

Derivative Instruments And Hedging Activities (Tables)	3 Months Ended
	Sep. 30, 2014
Derivative Instruments And Hedging Activities [Abstract]	'
Summary Of Amount And Location Of Derivative Financial Instruments	'
			30-Sep-14		30-Jun-14		Balance Sheet Caption
		Foreign currency hedging instruments	$	557	$	456		Other assets - current
		Foreign currency hedging instruments		518		489		Other assets - non current
		Foreign currency hedging instruments		-3,123		-3,215		Accrued expenses
			$	-2,048	$	-2,270
Summary Of Gains (Losses) Associated With Derivative Financial Instruments	'
			Gain /(Loss) Recognized				Income Statement Caption
			Three Months Ended September 30,
			2014		2013
		Foreign currency hedging instruments	$	-11,054	$	-3,156		Other, net
		Other foreign-currency-denominated transactions		12,148		1,741		Other, net
			$	1,094	$	-1,415

Earnings_Per_Share_Narrative_D

Earnings Per Share (Narrative) (Details)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'
Stock options not included in the computation of diluted earnings per share	154,551	209,856

Earnings_Per_Share_Schedule_Of

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'
Net Income, used in calculating diluted earnings per share	$83,260	$80,930
Basic weighted-average common shares outstanding	140,127	142,005
Effect of dilutive securities, stock options and restricted stock units	2,556	3,451
Diluted weighted average shares	142,683	145,456
Basic earnings per share	$0.59	$0.57
Diluted earnings per share	$0.58	$0.56

Inventories_Schedule_Of_Invent

Inventories (Schedule Of Inventories) (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$58,024	$53,680
Work in progress	3,761	3,358
Finished goods	135,441	108,380
Total inventories	$197,226	$165,418

Property_Plant_And_Equipment_D

Property, Plant And Equipment (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$813,560	$842,527
Accumulated depreciation and amortization	-393,774	-408,250
Property, plant and equipment, net	419,786	434,277
Machinery And Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	196,401	200,929
Computer Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	135,868	133,157
Furniture And Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	41,168	42,631
Vehicles [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	3,583	4,757
Clinical, Demonstration And Rental Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	93,503	101,453
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	29,032	30,361
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	59,494	62,468
Buildings [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, gross	$254,511	$266,771

CostMethod_Investments_Narrati

Cost-Method Investments (Narrative) (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Jun. 30, 2013
In Thousands, unless otherwise specified
Cost-Method Investments [Abstract]	'	'	'	'
Aggregate carrying amount of cost-method investments	$15,350	$14,850	$4,675	$4,000

CostMethod_Investments_Schedul

Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cost-Method Investments [Abstract]	'	'
Balance at the beginning of the period	$14,850	$4,000
Investments	500	675
Balance at the end of the period	$15,350	$4,675

Goodwill_And_Other_Intangible_2

Goodwill And Other Intangible Assets, Net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Goodwill And Other Intangible Assets, Net [Abstract]	'	'
Balance at the beginning of the period	$289,312	$274,829
Business acquisition	6,454	'
Foreign currency translation adjustments	-18,502	8,616
Balance at the end of the period	$277,264	$283,445

Goodwill_And_Other_Intangible_3

Goodwill And Other Intangible Assets, Net (Schedule Of Other Intangible Assets) (Details) (USD $)

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

In Thousands, unless otherwise specified

Developed/Core Product Technology [Member]

Developed/Core Product Technology [Member]

Trade Names [Member]

Trade Names [Member]

Non Compete Agreements [Member]

Non Compete Agreements [Member]

Customer Relationships [Member]

Customer Relationships [Member]

Patents [Member]

Patents [Member]

Minimum [Member]

Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other intangibles, gross

'

'

$70,677

$76,015

$2,803

$2,784

$1,982

$2,135

$28,368

$24,593

$67,872

$70,734

'

'

Accumulated amortization

'

'

-51,642

-54,073

-2,508

-2,697

-1,715

-1,768

-19,834

-20,877

-49,521

-51,648

'

'

Total other intangibles, net

$46,482

$45,198

$19,035

$21,942

$295

$87

$267

$367

$8,534

$3,716

$18,351

$19,086

'

'

Intangible assets, estimated useful life

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'9 years

LongTerm_Debt_Narrative_Detail

Long-Term Debt (Narrative) (Details) (USD $)	3 Months Ended
	Sep. 30, 2014	Oct. 31, 2013
Line of Credit Facility [Line Items]	'	'
Amount outstanding under credit facility	$375,000,000	'
Union Bank, N.A. and HSBC Bank USA [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Credit facility termination date	31-Oct-18	'
Interest rate on outstanding principal amount	1.20%	'
Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Maximum borrowing capacity	'	700,000,000
Credit facility term, years	'5 years	'
Uncommitted option to increase credit facility	300,000,000	'
Union Bank, N.A. and HSBC Bank USA [Member] | Letters Of Credit [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Maximum borrowing capacity	'	$25,000,000
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Commitment fees percentage rate on unused portion of credit facility	0.15%	'
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Credit facility interest rate equal to reference rate plus	1.00%	'
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Commitment fees percentage rate on unused portion of credit facility	0.25%	'
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]	'	'
Line of Credit Facility [Line Items]	'	'
Credit facility interest rate equal to reference rate plus	2.00%	'

LongTerm_Debt_Schedule_Of_Long

Long-Term Debt (Schedule Of Long-Term Debt) (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Long-Term Debt [Abstract]	'	'
Current long-term debt	'	$18
Non-current long-term debt	375,701	300,770
Total long-term debt	$375,701	$300,788

Product_Warranties_Details

Product Warranties (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Product Warranties [Abstract]	'	'
Balance at the beginning of the period	$11,798	$16,011
Warranty accruals for the period	3,376	2,796
Warranty costs incurred for the period	-1,567	-2,270
Foreign currency translation adjustments	-714	368
Balance at the end of the period	$12,893	$16,905

StockBased_Employee_Compensati2

Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected option life in years	'0 years	'0 years
ESPP Purchase Rights [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted average risk-free interest rate	0.10%	0.10%
Expected option life in years	'6 months	'6 months
Dividend yield	2.00%	1.44%
Expected volatility	24.00%	24.00%

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014	Apr. 30, 1997
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Common shares repurchased	800,000	400,000	'	'
Cost of common shares repurchased	$42,900,000	$21,100,000	'	'
Additional shares that can be repurchased under the approved share repurchase program	17,400,000	'	'	'
Number of shares repurchased pursuant to the repurchase program	37,277,982	'	36,442,495	'
Cost of shares repurchased pursuant to the repurchase program	1,334,782,000	'	1,291,910,000	'
Preferred stock, shares authorized	2,000,000	'	2,000,000	2,000,000
Preferred stock at par value	$0.01	'	$0.01	$0.01
Preferred stock, shares issued	0	'	0	'
Preferred stock, shares outstanding	0	'	0	'
Stock option and restricted stock units expiration period	'7 years	'	'	'
Common stock authorized for issuance	43,700,000	'	'	'
Number of securities remaining available for future issuance	16,200,000	'	'	'
Reduction in the number of shares of common stock available for issuance	2.8	'	'	'
Maximum number of shares subject to awards granted	3,000,000	'	'	'
Number of common stock shares granted in participant's initial year of hiring	4,500,000	'	'	'
Unrecognized compensation costs related to unvested stock-based compensation arrangements	62,100,000	'	'	'
Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements	'2 years 1 month 6 days	'	'	'
Aggregate intrinsic value of the stock-based compensation arrangements outstanding	225,000,000	'	'	'
Aggregate intrinsic value of the stock-based compensation arrangements exercisable	93,900,000	'	'	'
Aggregate intrinsic value of the options exercised	9,700,000	11,500,000	'	'
Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Number of securities remaining available for future issuance	1,800,000	'	'	'
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant	85.00%	'	'	'
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase	85.00%	'	'	'
Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock options and restricted stock units vesting period	'1 year	'	'	'
Minimum [Member] | Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Employee stock purchase program offering period	'3 months	'	'	'
Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock options and restricted stock units vesting period	'4 years	'	'	'
Maximum [Member] | Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Employee stock purchase program offering period	'27 months	'	'	'
Common stock shares subscribed	$25,000	'	'	'

Stockholders_Equity_Schedule_O

Stockholders' Equity (Schedule Of Option Activity) (Details) (USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014
Stockholders' Equity [Abstract]	'	'
Options, Outstanding at beginning of period	4,687,220	'
Options, Exercised	-297,969	'
Options, Forfeited	-13,823	'
Options, Outstanding at end of period	4,375,428	4,687,220
Options exercisable at end of period	3,399,349	'
Weighted Average Exercise Price, Outstanding at beginning of period	$24.45	'
Weighted Average Exercise Price, Exercised	$18.56	'
Weighted Average Exercise Price, Forfeited	$34	'
Weighted Average Exercise Price, Outstanding at end of period	$24.82	$24.45
Weighted Average Exercise Price, Options exercisable at end of period	$21.66	'
Weighted Average Remaining Term to Vest in Years, Outstanding	'2 years 4 months 24 days	'2 years 7 months 6 days

Stockholders_Equity_Schedule_O1

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) (Restricted Stock Units (RSUs) [Member], USD $)	3 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014
Restricted Stock Units (RSUs) [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Restricted Stock Units, Outstanding at beginning of period	2,448,331	'
Restricted Stock Units, Granted	1,500	'
Restricted Stock Units, Vested	-33,149	'
Restricted Stock Units, Forfeited	-24,189	'
Restricted Stock Units, Outstanding at end of period	2,392,493	2,448,331
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$38.58	'
Weighted Average Grant-Date Fair Value, Granted	$47.08	'
Weighted Average Grant-Date Fair Value, Vested	$30.95	'
Weighted Average Grant-Date Fair Value, Forfeited	$36.86	'
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$38.70	$38.58
Weighted Average Remaining Contractual Term in Years, Outstanding	'1 year 1 month 6 days	'1 year 3 months 18 days

Fair_Value_Measurements_Summar

Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedging instruments, net	($2,048)	($2,270)
Business acquisition contingent consideration	-875	-480
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedging instruments, net	'	'
Business acquisition contingent consideration	'	'
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign currency hedging instruments, net	-2,048	-2,270
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Business acquisition contingent consideration	($875)	($480)

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Fair Value Measurements [Abstract]	'
Balance at the beginning of the period	($480)
Acquisition date fair value of contingent consideration	-905
Changes in fair value included in operating income	132
Payments	458
Foreign currency translation adjustments	-80
Balance at the end of the period	($875)

Legal_Actions_And_Contingencie1

Legal Actions And Contingencies (Details) (Obligation to Repurchase Receivables Sold [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014
Obligation to Repurchase Receivables Sold [Member]	'	'	'
Loss Contingencies [Line Items]	'	'	'
Receivables sold to leasing companies under debt factoring arrangements	$2	$0.80	'
Maximum potential contingent liability	5.2	'	4.9
Recourse liability recognized	$0.50	'	$0.50

Derivative_Instruments_And_Hed2

Derivative Instruments And Hedging Activities (Narrative) (Details) (USD $)	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2014
In Millions, unless otherwise specified			Foreign Currency Contracts [Member]
Derivative [Line Items]	'	'	'
Terms of foreign currency hedging contracts, maximum	'	'	'3 years
Notional amount of foreign currency hedging contracts held	$405.80	$473.70	'

Derivative_Instruments_And_Hed3

Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) (Foreign Currency Contracts [Member], USD $)	Sep. 30, 2014	Jun. 30, 2014
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Assets (Liabilities)	($2,048)	($2,270)
Other Current Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Assets	557	456
Other Noncurrent Assets [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Assets	518	489
Accrued Expenses [Member]	'	'
Derivatives, Fair Value [Line Items]	'	'
Fair Value - Liabilities	($3,123)	($3,215)

Derivative_Instruments_And_Hed4

Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) (Derivatives Not Designated As Hedging Instruments [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Gain (Loss) Recognized in Income	$1,094	($1,415)
Foreign Currency Contracts [Member] | Other, Net [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Foreign currency-hedging instruments	-11,054	-3,156
Other Foreign-currency-denominated Transactions [Member] | Other, Net [Member]	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'
Other foreign-currency-denominated transactions	$12,148	$1,741

Business_Combinations_Details

Business Combinations (Details) (USD $)	3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Jun. 30, 2013
	entity
Business Acquisition [Line Items]	'	'	'	'
Number of businesses acquired	2	'	'	'
Goodwill	$277,264,000	$289,312,000	$283,445,000	$274,829,000
Customer Relationships [Member] | Series of Individually Immaterial Business Acquisitions [Member]	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'
Intangible assets	6,000,000	'	'	'
Intangible assets, useful life	'5 years	'	'	'
Goodwill	$6,500,000	'	'	'